JP2024534116A5 - - Google Patents

Info

Publication number
JP2024534116A5
JP2024534116A5 JP2024511969A JP2024511969A JP2024534116A5 JP 2024534116 A5 JP2024534116 A5 JP 2024534116A5 JP 2024511969 A JP2024511969 A JP 2024511969A JP 2024511969 A JP2024511969 A JP 2024511969A JP 2024534116 A5 JP2024534116 A5 JP 2024534116A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
chain complementarity
pharmaceutical composition
specified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024511969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534116A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/041395 external-priority patent/WO2023028159A1/en
Publication of JP2024534116A publication Critical patent/JP2024534116A/ja
Publication of JP2024534116A5 publication Critical patent/JP2024534116A5/ja
Pending legal-status Critical Current

Links

JP2024511969A 2021-08-25 2022-08-24 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法 Pending JP2024534116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163236953P 2021-08-25 2021-08-25
US63/236,953 2021-08-25
PCT/US2022/041395 WO2023028159A1 (en) 2021-08-25 2022-08-24 Methods of treating cancers associated with immunosuppressive b cells

Publications (2)

Publication Number Publication Date
JP2024534116A JP2024534116A (ja) 2024-09-18
JP2024534116A5 true JP2024534116A5 (https=) 2025-08-29

Family

ID=85322012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024511969A Pending JP2024534116A (ja) 2021-08-25 2022-08-24 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法

Country Status (9)

Country Link
US (1) US20240392000A1 (https=)
EP (1) EP4392062A4 (https=)
JP (1) JP2024534116A (https=)
KR (1) KR20240055016A (https=)
CN (1) CN118139639A (https=)
AU (1) AU2022332971A1 (https=)
CA (1) CA3229824A1 (https=)
IL (1) IL310941A (https=)
WO (1) WO2023028159A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220159989A (ko) 2020-02-26 2022-12-05 바이오그래프 55, 인크. C19 c38 이중특이적 항체
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6594855B2 (ja) * 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
EA037548B1 (ru) * 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
WO2021173844A1 (en) * 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies

Similar Documents

Publication Publication Date Title
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
JP7842703B2 (ja) 抗Ｃｌａｕｄｉｎ１８．２抗体およびその使用
KR102022734B1 (ko) 신규 조절제 및 용법
JP2021510736A5 (https=)
JP6421371B2 (ja) トランスポーターに対する抗体およびその用途
JP2022533538A5 (https=)
JP7533897B2 (ja) 融合タンパク質およびその使用
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
HUE030130T2 (en) A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
JP2024531409A5 (https=)
CN106699891A (zh) 一种抗pd‑l1 抗体、其药物组合物及其用途
JP2018510617A5 (https=)
JP2021500916A5 (https=)
JP2023540526A5 (https=)
JP2023517753A5 (https=)
JP2024024114A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2021517459A5 (https=)
JP2024540148A5 (https=)
JP2021522303A5 (https=)
JP2023544143A5 (https=)
JP2024534116A5 (https=)
JP2021512652A5 (https=)
JP2024516098A5 (https=)
JP2023506017A5 (https=)